AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26806596 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands and knees position for at least 10 minutes
Number of subjects: 439
Study 26806596 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 439
Study 24323030 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 551
Study 24323030 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant
Number of subjects: 551
Study 22579722 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid tablet (∼1,000 μg)
Number of subjects: 16
Study 22579722 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin softgel capsule (∼1,000 μg)
Number of subjects: 16
Study 20805454 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem-cell transplantation (HSCT) from matched related donors (MRD) and matched unrelated donors (MUD)
Number of subjects: 844
Study 20805454 — intervention group
Group type: COMPARATOR
Intervention: No HSCT
Number of subjects: 844
Study 18073546 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ultrasound-assisted internal jugular venous catheterization
Number of subjects: 60
Study 18073546 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided skin-marking method
Number of subjects: 60
Study 16163525 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.65 g/kg) after prior task experience with visual degradation
Number of subjects: 42
Study 16163525 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual degradation after prior task experience under active alcohol (0.65 g/kg)
Number of subjects: 42
Study 16163525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive) after prior task experience with visual degradation
Number of subjects: 42
Study 16163525 — intervention group
Group type: COMPARATOR
Intervention: Control group repeating each active treatment
Number of subjects: 42
Study 12230903 — intervention group
Group type: EXPERIMENTAL
Intervention: Q Link Ally (QL) added to active mobile phone exposure
Number of subjects: 24
Study 12230903 — intervention group
Group type: COMPARATOR
Intervention: Active mobile phone exposure
Number of subjects: 24
Study 10545590 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (2 x 10^10 colony-forming units in capsules given twice daily during antimicrobial treatment)
Number of subjects: 119
Study 10545590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (indistinguishable in appearance and taste)
Number of subjects: 119
Study 10545590 — intervention group
Group type: COMPARATOR
Intervention: Lactobacillus GG and Placebo
Number of subjects: 119
Study 7570411 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (500 mg three times daily)
Number of subjects: 195
Study 7570411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (960 mg twice daily)
Number of subjects: 195
Study 7570411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 7570411 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin, Cotrimoxazole, or Placebo with oral corticosteroids
Number of subjects: 195
Study 7570411 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin, Cotrimoxazole, or Placebo
Number of subjects: 195
Study 2303333 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue/yellow sensitivity
Number of subjects: 30
Study 2303333 — intervention group
Group type: COMPARATOR
Intervention: Conventional perimetric sensitivity
Number of subjects: 30
Study 2303333 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue/yellow color‐contrast perimetry
Number of subjects: 30
Study 2303333 — intervention group
Group type: COMPARATOR
Intervention: Conventional (luminance‐increment) perimetry
Number of subjects: 30
Study 6985560 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (3 x 200 mg/d for 8 weeks)
Number of subjects: 22
Study 6985560 — intervention group
Group type: EXPERIMENTAL
Intervention: clofibrate (3 x 500 mg/d for 8 weeks)
Number of subjects: 22
Study 6985560 — intervention group
Group type: COMPARATOR
Intervention: bezafibrate and clofibrate
Number of subjects: 22
Study 6985560 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 22
Study 31995662 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 92
Study 31995662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 30103755 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting insecticidal nets (LLINs) usage
Number of subjects: 2000
Study 30103755 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria parasite prevalence
Number of subjects: 2000
Study 30103755 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-economic status impact on parasitaemia
Number of subjects: 2000
Study 30103755 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in parasitaemia
Number of subjects: 2000
Study 28594602 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus a nine-hour AS-focused intervention
Number of subjects: 41
Study 28594602 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 41
Study 24326780 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental knee effusion
Number of subjects: 0
Study 24326780 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 0
Study 24030946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 56
Study 24030946 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 56
Study 21173180 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole oral gel (85 mg thrice daily)
Number of subjects: 12
Study 19025522 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml (18 mg) hypobaric 0.6% lidocaine
Number of subjects: 150
Study 19025522 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml (24 mg) hypobaric 0.6% lidocaine
Number of subjects: 150
Study 19025522 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml (30 mg) hypobaric 0.6% lidocaine
Number of subjects: 150
Study 16987361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided perivascular approach (Group US)
Number of subjects: 56
Study 16987361 — intervention group
Group type: COMPARATOR
Intervention: Transarterial technique (Group TA)
Number of subjects: 56
Study 16987361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 14550362 — intervention group
Group type: COMPARATOR
Intervention: General anaesthetic
Number of subjects: 127
Study 14550362 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic
Number of subjects: 127
Study 14550362 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic in clinic setting
Number of subjects: 127
Study 11037040 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg)
Number of subjects: 0
Study 11037040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9483755 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 24
Study 9483755 — intervention group
Group type: COMPARATOR
Intervention: No oral contraceptives (control group)
Number of subjects: 24
Study 8318401 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical therapy with 50% enhancement of median survival time (to 5.1 years)
Number of subjects: 500
Study 8318401 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical therapy with 50% enhancement of cured fraction (to 40.5%)
Number of subjects: 500
Study 3488140 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 20
Study 3488140 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 20
Study 3488140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29542816 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive attention bias modification training (ABMT)
Number of subjects: 60
Study 29542816 — intervention group
Group type: COMPARATOR
Intervention: Control condition (50% positive stimuli)
Number of subjects: 60
Study 27707440 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4,000 IU daily)
Number of subjects: 19
Study 27707440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 26277173 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight children
Number of subjects: 60
Study 23766519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol (D₃) 600,000 IU
Number of subjects: 24
Study 23766519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ergocalciferol (D₂) 600,000 IU
Number of subjects: 24
Study 23766519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular cholecalciferol (D₃) 600,000 IU
Number of subjects: 24
Study 23766519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ergocalciferol (D₂) 600,000 IU
Number of subjects: 24
Study 21112864 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/day)
Number of subjects: 30
Study 21112864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18405151 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment (routine western medicine combined with acupuncture, moxibustion, and enema of Chinese drugs)
Number of subjects: 96
Study 18405151 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group (routine western methods including dehydration, brain-protection, anti-platelet agglutination, improving circulation, and expectant treatment)
Number of subjects: 96
Study 17027422 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial Protocol Tool (developed in English and Spanish)
Number of subjects: 0
Study 17027422 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial Protocol Tool
Number of subjects: 0
Study 14728759 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation system
Number of subjects: 21
Study 14728759 — intervention group
Group type: COMPARATOR
Intervention: Usual face-to-face method (Control)
Number of subjects: 21
Study 11590492 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 1 (didanosine 400 mg/day, stavudine 60/80 mg/day, and HU 500 mg/day)
Number of subjects: 284
Study 11590492 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 3 (didanosine, indinavir, and HU 500-1,000 mg/day)
Number of subjects: 284
Study 11590492 — intervention group
Group type: COMPARATOR
Intervention: Treatment 2 (two nucleosides plus a protease inhibitor)
Number of subjects: 284
Study 11590492 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 1
Number of subjects: 284
Study 11590492 — intervention group
Group type: COMPARATOR
Intervention: Treatment 2
Number of subjects: 284
Study 8774217 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar wheatflake meal (6.3 g guar gum)
Number of subjects: 10
Study 8774217 — intervention group
Group type: COMPARATOR
Intervention: Control meal (0 g guar gum)
Number of subjects: 10
Study 1534642 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release nicardipine
Number of subjects: 28
Study 6377152 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose tolerance test
Number of subjects: 46
Study 6377152 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymer tolerance test
Number of subjects: 46
Study 31449090 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced testing, linkage to care, and ARV treatment in 15 intervention villages.
Number of subjects: 100000
Study 29310703 — intervention group
Group type: EXPERIMENTAL
Intervention: Floseal® (Baxter, USA)
Number of subjects: 0
Study 29310703 — intervention group
Group type: COMPARATOR
Intervention: Traditional nasal packing
Number of subjects: 0
Study 26632428 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg melatonin (Melaxen(TM)) daily at 22:30 h for two weeks
Number of subjects: 97
Study 26632428 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 97
Study 24958736 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/LV (UFT 300 mg m(‐2) day(‐1), LV 75 mg/day on days 1-28 every 5 weeks)
Number of subjects: 1101
Study 24958736 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/l‐LV (5‐FU 500 mg/m(2), l‐LV 250 mg/m(2) on days 1, 8, 15, 22, 29, 36 every 8 weeks)
Number of subjects: 1101
Study 24958736 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT/LV
Number of subjects: 1101
Study 24958736 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/l‐LV
Number of subjects: 1101
Study 22429357 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil TCI with desflurane
Number of subjects: 48
Study 22429357 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil TCI with sevoflurane
Number of subjects: 48
Study 22429357 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil TCI for preventing cough during emergence from desflurane anaesthesia
Number of subjects: 48
Study 19769614 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 231
Study 19769614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 17825800 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75-300 mg/day)
Number of subjects: 821
Study 17825800 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20-60 mg/day)
Number of subjects: 821
Study 17825800 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (continuation phase)
Number of subjects: 821
Study 17825800 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (continuation phase)
Number of subjects: 821
Study 16362597 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin 5 mg daily for one month
Number of subjects: 90
Study 16362597 — intervention group
Group type: COMPARATOR
Intervention: Placebo for one month
Number of subjects: 90
Study 16362597 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin 10 mg after one month for group 2 and those with improvement or ineffectiveness from 5 mg
Number of subjects: 90
Study 12133195 — intervention group
Group type: EXPERIMENTAL
Intervention: New evidence-based antenatal care model
Number of subjects: 1600
Study 12133195 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care model
Number of subjects: 1600
Study 10080319 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported mandibular overdenture on a transmandibular implant (TMI)
Number of subjects: 3
Study 10080319 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-tissue-supported mandibular overdenture on two IMZ implants (IMZ)
Number of subjects: 3
Study 10080319 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete dentures (CD)
Number of subjects: 3
Study 7562122 — intervention group
Group type: EXPERIMENTAL
Intervention: One-month intensive training centered on psychosocial skills
Number of subjects: 26
Study 1539851 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 200 U/kg and additional heparin as needed to maintain ACT > 400 s (group A, n = 30)
Number of subjects: 63
Study 1539851 — intervention group
Group type: COMPARATOR
Intervention: Heparin 400 U/kg and additional heparin as needed to maintain whole blood heparin concentration > 4.0 U/ml (group H, n = 33)
Number of subjects: 63
Study 3895948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 74
Study 3895948 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 74
Study 30094732 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 825
Study 30094732 — intervention group
Group type: COMPARATOR
Intervention: Granisetron
Number of subjects: 825
Study 29545471 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS
Number of subjects: 239
Study 29545471 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS death
Number of subjects: 239
Study 29545471 — intervention group
Group type: EXPERIMENTAL
Intervention: TB/HIV
Number of subjects: 239
Study 29545471 — intervention group
Group type: EXPERIMENTAL
Intervention: TB/HIV death
Number of subjects: 239
Study 29545471 — intervention group
Group type: EXPERIMENTAL
Intervention: LTBI/HIV
Number of subjects: 239
Study 27098551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (IV-D)
Number of subjects: 288
Study 27098551 — intervention group
Group type: COMPARATOR
Intervention: Oral dexamethasone (PO-D)
Number of subjects: 288
Study 25140086 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromobilization combined with routine physiotherapy
Number of subjects: 20
Study 25140086 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 20
Study 22560728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 109
Study 22560728 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Number of subjects: 109
Study 20218793 — intervention group
Group type: COMPARATOR
Intervention: Usual starting dose of SSRIs (10 mg escitalopram; 20 mg fluoxetine, paroxetine, citalopram; 50 mg sertraline and fluvoxamine)
Number of subjects: 2340
Study 20218793 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher starting doses of SSRIs
Number of subjects: 2340
Study 20218793 — intervention group
Group type: COMPARATOR
Intervention: Usual starting dose of SSRIs
Number of subjects: 2340
Study 18767581 — intervention group
Group type: EXPERIMENTAL
Intervention: Turtle probing the cave needling method (acupuncture therapy), treated once a day for two weeks.
Number of subjects: 60
Study 18767581 — intervention group
Group type: COMPARATOR
Intervention: Motilium (10 mg oral administration, thrice daily, 30 minutes before meals, for two weeks).
Number of subjects: 60
Study 15982149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 74
Study 15982149 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (present-centered therapy; PCT)
Number of subjects: 74
Study 15982149 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 74
Study 12066947 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 100
Study 12066947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9737828 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg lubeluzole
Number of subjects: 12
Study 9737828 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lubeluzole
Number of subjects: 12
Study 9737828 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lubeluzole
Number of subjects: 12
Study 9737828 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of lubeluzole (5, 10, 15 mg)
Number of subjects: 12
Study 9737828 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of lubeluzole
Number of subjects: 12
Study 7918310 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid ethyl esters (3 g/d) administered to healthy volunteers for 18 weeks
Number of subjects: 30
Study 7918310 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acid ethyl esters (3 g/d) administered to hypertriglyceridemic patients for 24 weeks
Number of subjects: 30
Study 3042399 — intervention group
Group type: EXPERIMENTAL
Intervention: Endomyocardial biopsy
Number of subjects: 91
Study 3042399 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium-67 myocardial scintigraphy
Number of subjects: 91
Study 30312163 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary Spiritist Therapy (3 days, 10 mins per day/session) alongside conventional treatment
Number of subjects: 41
Study 30312163 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone
Number of subjects: 41
Study 27616732 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% maltodextrin solution (CHO)
Number of subjects: 11
Study 27616732 — intervention group
Group type: EXPERIMENTAL
Intervention: 14% maltodextrin solution (CHO)
Number of subjects: 11
Study 27616732 — intervention group
Group type: COMPARATOR
Intervention: Taste-matched placebo (PLA)
Number of subjects: 11
Study 27616732 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 11
Study 27616732 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE
Number of subjects: 11
Study 27616732 — intervention group
Group type: EXPERIMENTAL
Intervention: GI comfort
Number of subjects: 11
Study 25795276 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive language input (highly predictable words)
Number of subjects: 0
Study 25795276 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive arrow cues
Number of subjects: 0
Study 25795276 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocabulary size and verbal fluency
Number of subjects: 0
Study 25795276 — intervention group
Group type: COMPARATOR
Intervention: Control object (unrelated object)
Number of subjects: 0
Study 24103519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleaginous extract of kale (50 mL providing 10 mg lutein and 3 mg zeaxanthin per day)
Number of subjects: 20
Study 24103519 — intervention group
Group type: COMPARATOR
Intervention: Refined rapeseed oil (placebo)
Number of subjects: 20
Study 24103519 — intervention group
Group type: EXPERIMENTAL
Intervention: Kale group
Number of subjects: 20
Study 21118623 — intervention group
Group type: EXPERIMENTAL
Intervention: Infloran(®) stored at 4°C
Number of subjects: 0
Study 21118623 — intervention group
Group type: EXPERIMENTAL
Intervention: Infloran(®) stored at room temperature (28-32°C)
Number of subjects: 0
Study 21118623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18651320 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily
Number of subjects: 40
Study 18651320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16556674 — intervention group
Group type: EXPERIMENTAL
Intervention: Echogenic catheter
Number of subjects: 193
Study 16556674 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 193
Study 14519051 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug therapy
Number of subjects: 281
Study 14519051 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 281
Study 14519051 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 281
Study 14519051 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers and diuretics
Number of subjects: 281
Study 14519051 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 281